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Cytotoxicity of oc-particle-emitting astatine-21 I Iabelled
antibody in tumour spheroids: no effect of hyperthermia
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Summary The high linear energy transfer, a-particle-emitting radionuclide astatine-211 (21'At) is of interest for certain therapeutic
applications; however, because of the 55- to 70-jim path length of its a-particles, achieving homogeneous tracer distribution is critical.
Hyperthermia may enhance the therapeutic efficacy of a-particle endoradiotherapy if it can improve tracer distribution. In this study, we have
investigated whether hyperthermia increased the cytotoxicity of an 21'At-labelled monoclonal antibody (MAb) in tumourspheroids with a radius
(approximately 100gm) greater than the range of 21'At a-particles. Hyperthermia for 1 h at 420C was used because this treatment itself
resulted in no regrowth delay. Radiolabelled chimeric MAb 81C6 reactive with the extracellular matrix antigen tenascin was added to
spheroids grown from the D-247 MG human glioma cell line at activity concentrations ranging from 0.125 to 250 kBq ml-'. A significant
regrowth delay was observed at 125 and 250 kBq ml-' in both hyperthermia-treated and untreated spheroids. For groups receiving
hyperthermia, no increase in cytotoxicity was seen compared with normothermic controls at any activity concentration. These results and
those from autoradiographs indicate that hyperthermia at 420C for 1 h had no significant effect on the uptake or distribution of this anti-
tenascin MAb in D-247 MG spheroids.
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The use of a-particle-emitting radionuclides for endoradiotherapy
has several potential advantages compared with 1-emitters. The
high linear energy transfer (LET) of a-particles makes them
highly cytotoxic, rendering even hypoxic cells vulnerable. In addi-
tion, a-particles have relatively short effective path lengths in
tissue, decreasing the radiation delivered to normal tissues located
in close proximity to the tumour. For example, the mean path
length of the a-particles emitted by 7.2-h half-life 21'At is 55-
70gm compared with 800gm for the 5-particles emitted by '3'I
(Gaze et al, 1992; Zalutsky, 1994). In contrast, the short a-particle
range is potentially problematic because of the necessity for
achieving homogeneous distribution of the radionuclide in the
tumour for effective therapy. The limited range of a-particles has
led investigators to focus therapeutic applications in which the
tumour is present in thin sheets, such as neoplastic meningitis and
peritoneal metastasis. The efficacy of 21'At-labelled monoclonal
antibodies (MAbs) in a rat model of neoplastic meningitis has
been encouraging (Zalutsky et al, 1994).
Micrometastatic disease could offer another potential applica-
tion of a-emitters if sufficiently homogeneous tracer distribution
could be achieved. The determination of the most appropriate
radionuclide for the treatment of small volume disease has been
the focus ofboth experimental and theoretical studies (Humm and
Cobb, 1990; Langmuir et al, 1990; 1992a). Ifhomogeneous distri-
bution can be achieved, a-emitters such as 21'At yield a much
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higher absorbed dose fraction within the tumour compared with
long-range 3-emitters such as 90Y, particularly for lesions of less
than 1 cm diameter. In addition, specific targeting ofradionuclide
to cell membranes compared with a random distribution of decay
sites within the tumour would offer the largest enhancement for
211At (Humm and Cobb, 1990). For these reasons, targeted radio-
therapy with a-particle emitters has potential for the treatment of
micrometastatic disease.
Hyperthermia has been proposed as a technique for improving
the homogeneity of the distribution of radiotherapeutics within
solid tumours (Gridley et al, 1991). In the current study, we have
investigated the effect of concurrent administration of hyper-
thermia at 42°C on the cytotoxicity of 21'At-labelled chimeric
81C6 MAb (ch8lC6) in spheroids grown from the D-247 MG
human glioma line. These parameters were selected because
previous studies have shown that hyperthermia at 42°C markedly
enhanced the uptake of radioiodinated ch8lC6 in human glioma
xenografts (Hauck et al, 1997) and because ofthe clinical interest
in treating central nervous system malignancies with radiolabelled
81C6 MAb (Bigner et al, 1995).
MATERIALS AND METHODS
Cell line and spheroid propagation
The D-247 MG cell line, derived from a biopsy of a gliosarcoma,
was established in the laboratory ofDr Darell Bigner and supplied
by him for these studies (Bigner et al, 1988). Before the initiation
ofthese experiments, the cell line was demonstrated to be negative
for mycoplasma by hybridization with a radiolabelled RNA probe
for mycoplasma ribosomal RNA. Exponentially growing D-247
MG cells were harvested with 0.25% trypsin-0.02% EDTA and
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viable cells were counted by trypan blue exclusion. RPMI-1640
medium (components purchased from JRH Biosciences, Lenexa,
KS, USA) supplemented with 10% fetal calfserum, 2 mm L-gluta-
mine, penicillin (50 U ml-') and streptomycin (50 jg ml-') was
used for all experiments and hereafter is designated as complete
medium. Afterdetermining theirviability, 2 x 106 cells were added
to 80 ml of complete medium in stirrer flasks at 30 r.p.m. and
placed in an incubator at 37°C in a 5% carbon dioxide atmosphere.
Spheroids were used in experiments 7 or 8 days after the start of
the culture. Measurements of the surface area at the maximum
diameter of each spheroid, made with the NIH image program,
were used to calculate spheroid radius and volume. The spheroids
used in the higher activity concentration experiment had an
average radius of 103 ± 10 jm and an average volume of
(4.69 ± 1.54) x 106 im3 at the start ofthe experiment.
Radiolabelled MAb
These experiments used the human/mouse chimeric construct of
81C6 (ch81C6) consisting ofthe human IgG2 constant regions and
murine 81C6 variable regions. The construction, purification and
characterization of ch8lC6, which reacts with the extracellular
matrix antigen tenascin, has been described in a previous publica-
tion (He et al, 1994). Astatine-211 was produced via the
209Bi(a,2n)2"'At reaction at the Duke University Medical Center
cyclotron by irradiating bismuth metal targets with 28-MeV
a-particles (Larsen et al, 1996). The 21'At activity was isolated
from the cyclotron target by dry distillation into chloroform.
N-succinimidyl 3-[21'At]astatobenzoate was synthesized, purified
and coupled to ch8lC6 according to previously published proce-
dures (Zalutsky et al, 1994). The specific activity of21'At-labelled
ch8lC6 ranged between 30 and 52 kBq jg-'. Sodium [1251]iodide
was obtained from DuPont New England Nuclear (North Billerica,
MA, USA) and analogous procedures were used to produce 1251-
labelled ch81C6 for autoradiography. An isotype-matched control
MAb, TPS3.2 (Dangl et al, 1988), as well as ch8lC6 were labelled
with 1251 for the binding studies using a modification of the lodo-
Gen method (Fraker and Speck, 1978). Specific binding in vitro to
D-54 MG tenascin-positive glioma homogenate was greater than
80% and trichloroacetic acid precipitation demonstrated that at
least 98% of the radioactivity was protein-bound for all labelled
ch81C6 preparations.
Spheroid autoradiography
Spheroids were incubated with either 1 or 10 jg ml-' of 1251-
labelled ch81C6 for 1-48 h at either 37 or 42°C. Spheroids were
washed three times with fresh medium to remove unbound MAb,
collected and embedded in Tissue-Tek OCT embedding
compound (Miles, Elkhart, IN, USA) for the preparation of
cryosections. Cryosections (10 jim) were mounted on glass
slides coated with poly-L-lysine (Sigma). After fixation in
methanol-isopropyl alcohol-acetone (50:40:10), slides were
dipped in NTB-3 autoradiography emulsion (Kodak) and dried in
a slanted position for several hours in the dark. The slides were
then exposed at 4°C for 1 week. Slides were developed with
Dektol developer and fixer (Kodak) according to the manufac-
turer's instructions. A standard haematoxylin and eosin counter-
stain was applied.
Binding of ch8lC6 to D-247 MG spheroids
Aliquots of ten spheroids of similar diameter to those used in the
cytotoxicity assays were individually selected on an inverted
microscope and placed in Eppendorf tubes with Hepes-buffered
complete medium. Because unlabelled ch81C6 was added to some
groups in the cytotoxicity assay, a group of spheroids were incu-
bated with unlabelled ch8lC6 at an about 40-fold excess for at
least 1 h before the selection of spheroids for the binding analysis.
This was carried out to determine the effect of the excess unla-
belled MAb on binding ofthe radiolabelled ch8lC6. Non-specific
uptake ofradiolabelled MAb was also assessed. For analysis ofthe
kinetics of MAb binding to spheroids, '251-labelled ch8lC6 or
'25I-labelled TPS3.2 were added to a final concentration of
250 kBq ml-' and spheroids were placed on arotator at 37 or42°C.
At selected time intervals (1, 2, 4, 8 and 24 h), spheroids were
removed and the medium was aspirated and twice replaced with
fresh medium to remove unbound MAb. Excess medium was aspi-
rated, and the spheroids transferred to a clean tube for counting of
bound radioactivity in a gamma-counter (1282 Compugamma,
LKB Wallac, Tiirkii, Finland). All measurements were performed
in triplicate.
To assess binding as a function of mAb activity concentration,
aliquots often spheroids were incubated for 1 h at 37 or42°C with
7.8-125 kBq ml-' of 125I-labelled MAb. The MAbs were labelled
with 125I at the same specific activity as the 21'At-labelled MAb
preparations used in the cytotoxicity assays to allow direct
comparison between 125I- and 2"'At-labelled MAbs. Spheroids
were washed, transferred to clean vials and bound activity counted
in the gamma-counter. All samples were performed in triplicate.
Counts per minute per spheroid were graphed as a function of
activity concentration in the medium.
Spheroidgrowth inhibition assays
In some groups, unlabelled ch8lC6 was added to the spinner
culture flask at protein concentrations ranging from 10 to
187.5 jig ml-' at least 1 h before the addition of 21'At-labelled
ch8lC6. This was carried out to inhibit specific binding of the
2"'At-labelled ch8lC6 and thereby increase its penetration within
the spheroid. These groups of spheroids, designated as low
specific activity controls, contained at least an approximately 40-
fold higher protein concentration of unlabelled MAb compared
with the highest activity concentration of211At-labelled ch81C6; at
lower activity concentrations of radiolabelled MAb, this resulted
in up to a 1000-fold excess ofcold ch81C6.
Apreliminary experiment was performed to determine a heating
protocol that would not have a cytotoxic effect on these spheroids.
As shown in Figure 1, 1 h ofheating at 42°C did not decrease the
growth rate of the spheroids, whereas longer hyperthermia treat-
ments inhibited spheroid regrowth. Samples (3 ml) of the spher-
oids suspended in complete medium were aliquoted into tubes,
2"lAt-labelled ch81C6 was added to the desired activity concentra-
tion (0.125 kBq ml-' to 250 kBq ml-'), and the volume adjusted to
4 ml. The low specific activity controls continued to have unla-
belled ch8lC6 in the medium containing 2"'At-labelled ch8lC6.
Tubes were placed in an incubator at 37°C or 42°C on a rotator
for 1 h. Then, the spheroids were washed twice using gravity
sedimentation, resuspended in complete medium and placed in
a sterile 15 x 60 mm Petri dish to select individual spheroids
forplating.
British Journal ofCancer(1998) 77(5), 753-759 0 CancerResearch Campaign 1998Hyperthermia and2lAt-labelled antibodycytotoxicity 755
lo
linear portion of the spheroid growth curve and the small initial
volume of the spheroids allowed this magnitude of growth to be
A achieved. A P < 0.05 (i.e. at the 95% level) was considered to be
significant.
RESULTS
// / The effect of hyperthermia on spheroid growth at 42°C is
/// ,/ presented in Figure 1. Hyperthermia treatments for time periods
longer than I h resulted in a significant delay in spheroid growth.
B /,' With longer heating periods, heating also affected spheroid phys-
/Y /' ical integrity. After a 2-h incubation at 42°C, spheroids shed
7/ ' numerous individual cells over several days. Spheroids heated for
4 h lost physical integrity, resulting in a large number of single
7 '7' cells and cell clumps spread on the agar. This partial disintegration
..v was manifested over the initial 10 days by an increase in spheroid
diameter as seen by the digitizing camera and imaging program;
0 2 4 6 8 10 12 however, visual inspection of the spheroids under the microscope
revealed that the apparent growth was due to cell shedding. Even
Days post heating the spheroids heated for 4 h at 42°C eventually demonstrated
evidence of regrowth, but in many cases spherical conformation
:tofhyperthermiaonspheroidregrowth; 370C(opensymbols), was lost. Heating for more than 1 h also caused an apparent
mbols) incubated for 30 min (0); 1 h (U); 2 h (A); 4 h (V) increase in the size of many of the cells.
The binding kinetics ofch8lC6 to spheroids were measured with
1251- instead of211At-labelled ch81C6 to avoid cytotoxicity at higher
he methodology of Gaze et al (1992), spheroids were doses and/or longer incubation times, and to improve count rate at
hosen and placed on soft agar (1.56%) overlaid with the conclusion of a 24-h study because ofthe longer half life of 1251.
dium, one spheroid per well, using the centre eight Even at an activity concentration of 250 kBq ml-', binding of 1251-
vell plates. The outer wells were filled with distilled labelled ch81C6 to D-247 MG spheroids continued to increase over
imize loss of medium by evaporation. Using a 20-pl 24 h, suggesting that antigen saturation had not occurred. After a
pheroids per treatment group were selected. After 1-h incubation at 250 kBq ml-1, an activity concentration of 7.1 Bq
urface area at the largest diameter of each spheroid per spheroid was reached. Binding of '25I-labelled ch8lC6 did not
I using the NIH Image software program (v. 1.52), a vary with temperature over the first 2 h, after which at 420C it
Ici personal computer and a Leitz microscope declined to the level reached by non-specific TPS3.2 MAb consis-
with a digitizing camera (Sony Model XC-711) as tent with the compromised spheroid integrity at longer heating
low. Spheroids were measured every other day for periods noted above. This study confmed that specific binding of
ntil a 40-fold increase in volume was seen. (At larger ch8lC6 occurred by 1 h. Binding to spheroids as a function of
spheroids began disintegrating.) Spheroids were fed medium activity concentration after a 1-h incubation is depicted in
200 gl of complete medium per well once a week. Figure 2. The absolute percentage of medium activity bound to the
spheroids was low. For example, with 250 and 125 kBq ml-'
is ch81C6, 2.8 x 10-3% and 5.0 x 10-3% ofthe activity in the medium,
area at the maximum diameter of the spheroid, respectively, was bound per spheroid at 370C.
ng the NIH Image program (v. 1.52), was used to The growth curves for D-247 MG spheroids incubated for 1 h
radius and volume of each spheroid assuming spher- with 4-250 kBq ml-1 of 211At-labelled MAbs at 37 and 42°C, as
r. The mean and standard deviation of the volume of well as those not exposed to labelled MAb, are presented in Figure
it group (n = 21-24 spheroids per group) was plotted 3. At 4 and 8 kBq ml-', no effect of 211At-labelled ch8lC6 on the
treatment. The mean value of the spheroid volumes growth rate of D-247 MG spheroids was observed at either
rather than the median because no spheroids were temperature. Incubation ofspheroids with 125 and 250 kBq ml-' of
is treatment protocol. Owing to contamination, only 211At-labelled ch8lC6 significantly delayed spheroid growth
heroids, respectively, were measured at days 25 and compared with controls. Table 1 summarizes the number of days
--plus-250 kBq ml-1 treatment group. Growth curves required for spheroids to achieve a 25-fold increase in volume for
on semilog axes, and a second-order regression fit controls and groups incubated with 67.5, 125, and 250 kBq ml-' of
nfidence interval was obtained using Sigma Plot 21'At-labelled ch8lC6. Similar trends were seen using a 30-fold
tific, San Rafael, CA, USA). The time to reach a 25- increase in volume end point; however, these end points generally
in volume was calculated, as well as the 95% confi- didnotoccuron the linearportion ofthe growth curve andthe 95%
1 for that time point. Previously published studies confidence intervals were very large. The initial volumes of the
1992) used a tenfold increase in volume as the end spheroids in these treatment groups were quite similar (Table 1).
er, because of the rapid growth rate of D-247 MG Correlation coefficients for the fit of the second-order regression
ifold increase in volume in approximately 4-5 days), line ranged between 0.964 and 1.000. There was no significant
n growth rate was seen at that end point. A 25-fold growth delay compared with 37°C controls for spheroid groups
)lume was selected because that end point lay on the (a) incubated at 42°C; (b) preincubated with unlabelled ch8lC6
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Figure 2 Binding of 1251-labelled ch8lC6 to spheroids after a 1-h incubation
at varying media activity concentrations. Incubation at either 370C (open
symbols) or 420C (closed symbols); (0, 0) 1251-labelled ch8lC6; (U)
spheroids preincubated with 40-fold excess unlabelled ch8lC6 before the
addition of 1251-labelled ch81C6; (A) 1251-labelled TPS3.2. Error bars indicate
one standard deviation. All measurements made in triplicate
(low specific activity controls); and (c) groups treated with
67.5 kBq ml. None of the low specific activity control groups
differed significantly from the temperature control groups.
Exposure to 125 and 250kBq ml-' of 21'At-labelled ch8lC6
resulted in a significant growth delay when compared with their
temperature and low specific activity control groups. However, at
all activity concentrations, hyperthermia had no effect on the
growth rate of the spheroids. Increasing the activity concentration
from 125 to 250 kBq mr-' resulted in a significant increase in
growth delay at both temperatures (Figure 3). Autoradiographs
(Figures 4 and 5) did not indicate that even prolonged heating (4 h)
of the spheroids at 42°C increased MAb penetration.
DISCUSSION
Local hyperthermia can improve the absolute level of MAb taken
up by tumours in vivo (Stickney et al, 1987; Cope et al, 1990;
Hauck et al, 1997). Although the mechanism by which hyper-
thermia exerts this effect is not known, alterations in MAb diffu-
sion rate within the tumour interstitium as well as changes in
antigen-MAb binding kinetics, vascular permeability and tumour
blood flow all may play a role. Hyperthermia can enhance the
cytotoxicity of low LET and low dose rate irradiation through
inhibition of repair of radiation-induced damage and suppression
of cell proliferation (Armour et al, 1991; Wang et al, 1992). Thus,
concurrent hyperthermia treatment could be useful not only for
increasing the tumour uptake of MAbs labelled with ,B-emitting
radionuclides but also for potentiating their cytotoxicity.
Moreover, as investigated in the current study, hyperthermia might
enhance the cytotoxicity of a-emitting endoradiotherapeutic
agents by increasing the homogeneity of their tumour uptake.
Multicellular tumour spheroids offer a three-dimensional
tumour model of micrometastatic disease (Walker et al, 1988;
Langmuir et al, 1990; Mairs et al, 1991; Gaze et al, 1992) in which
Table 1 Effect of 21'At-labelled ch8lC6 and temperature on D-247MG
spheroid growth
21'At activity (kBq ml-') Pretreatment radius Time to reach 25 x
(Rm)a volume (days)b
370C incubation
0 107± 11 8.7 (8.1-9.2)
67.5 103 ± 13 9.9 (9.2-10.7)
67.5 (LSA)p 105 ± 10 9.0 (8.6-9.4)
125 103 ± 9 10.9 (9.9-12.0)0
125 (LSA) 103 ± 14 8.6 (8.4-8.9)
250 99± 11 14.8 (13.2-16.5)*
250 (LSA) 100 ± 9 8.7 (8.5-8.9)
420C incubation
0 107 ± 11 8.7 (8.2-9.2)
67.5 103 ± 8 9.2 (8.7-9.7)
67.5 (LSA) 102 ± 9 8.7 (8.4-9.0)
125 97 ± 9 10.5 (9.6-11.4)-
125 (LSA) 103 ± 14 8.8 (8.6-9.0)
250 101 ± 9 16.0 (14.3-17.9)-
250 (LSA) 104 ± 11 8.6 (8.4-8.7)
aMean ± s.d; bmean value with 95% confidence interval; clow specific activity
control, i.e. preincubated with excess of unlabelled ch81C6; *significantly
different (P< 0.05) than no activity control.
to investigate this possibility without the influence of variable
vascular flow and permeability as well as elevated interstitial fluid
pressure, all of which can influence the uptake of targeted thera-
peutic agents (Baxter and Jain, 1989).
There is disagreement concerning the penetration ofMAbs into
tumour spheroids. Both specific and non-specific MAbs have been
reported to penetrate into the interior ofspheroids within 6 to 11 h
(McFadden and Kwok, 1988; Hjelstuen et al, 1996). In contrast, it
has been reported that intact MAbs targeted to cell membrane anti-
gens bind only to the outer 1-3 cell layers ofthe spheroid, whereas
MAb fragments penetrate 8-10 cell layers (Mairs et al, 1991).
Chen et al (1991) demonstrated that a MAb that binds to nuclear
histones penetrates to the necrotic centre of spheroids, implying
that the hindrance to homogeneous distribution is not inherently a
consequence of the size of MAbs but rather a function of their
binding to the first available antigen.
Spheroids are a valuable model for the evaluation of endo-
radiotherapeutics because they better represent the barriers to
homogeneous distribution in micrometastatic nodules than
monolayer cultures. In addition, because of their three-dimen-
sional structure, spheroids are an excellent model for studying
the effect of cross-fire on cell kill with radionuclides. A mathe-
matical model of MAb diffusion through tumour tissue has
demonstrated the importance ofusing a three-dimensional model
for evaluating distribution issues (El-Karch et al, 1993). By
calculating the effect of interstitial components on diffusion, it
was concluded that diffusion within a tumour nodule would be
decreased by 10- to 20-fold compared with diffusion through
water. The effects ofimpedance due to extracellular structures on
the delivery of macromolecules must be addressed to investigate
distribution on a cellular level. For these reasons, the tumour
spheroid model was selected to investigate further the potential
use of labelled MAbs in combination with hyperthermia, in
particular as it might apply to the treatment of micrometastatic
disease with 21'At-labelled MAbs.
British Journal of Cancer (1998) 77(5), 753-759 0CancerResearch Campaign 1998Hyperthermia and2lAt-labelled antibodycytotoxicity 757
A
1
I
0 2 4 6 8 10 12 14
DaysPoolaet~mUne Figure 4 Autoradiograph of '251-labelled ch8lC6 distribution in a D-247 MG
spheroid after a 4-h incubation at 370C taken at 250 x magnification. Section
counterstained with haematoxylin and eosin
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Figure 3 Growth of spheroids incubated at 370C (closed symbols) or 420C
(open symbols) for 1 h at varying concentrations of 211At-labelled ch8lC6.
Second-order regression curves are presented. Low specific activity controls
and intermediate activity concentrations eliminated for clarity. (A) (0, 0) No
labelled mAb (temperature controls); (-, El) 4 kBq mI-1 21'At-labelled ch8lC6;
(A, A) 8 kBq ml-1 21'At-labelled ch8lC6; (B) (0, 0) No labelled mAb; (-, O)
125 kBq ml-1 21'At-labelled ch8lC6; (A, A) 250 kBq mI-1 21'At-labelled ch8lC6
Although several investigators have achieved greater penetra-
tion of small molecules into spheroids by performing incubations
under hypothermic conditions (Cody et al, 1993; Wartenberg and
Acker, 1995), these results probably are not germane to our
attempt to use hyperthermia to achieve the same goal. In these
studies, increased penetration offluorescent dyes such as SNARF-
1 into spheroids was accomplished by performing incubations at
8-10°C. However, this effect was not related to increased molec-
ular diffusion; at room temperature, the dyes were being trapped in
the outer spheroid layers because ofdegradation by esterases.
Concurrent administration of 1 h ofhyperthermia at 42°C to the
D-247 MG spheroids failed to enhance the cytotoxicity of 21'At-
labelled ch81C6. In interpreting these results, it is important to
consider several ofthe mechanisms by which hyperthermia poten-
tially might enhance the effectiveness ofendoradiotherapy. Hyper-
thermia can enhance the cytotoxicity of low LET radiotherapy
Figure 5 Autoradiograph of '251-labelled ch8lC6 distribution in a D-247 MG
spheroid after a 4-h incubation at 420C taken at 250 x magnification. Section
counterstained with haematoxylin and eosin
through the inhibition ofrepair of sublethal damage; however, this
should not be a factor with high LET a-particles such as those
emitted by 211At (Gerner and Leith, 1977). Hyperthermia can
modulate cell membrane antigen expression (Wong et al, 1989;
Davies and Lindmo, 1990). Because ch8lC6 recognizes an extra-
cellular matrix protein, tenascin, this may decrease the likelihood
that hyperthermia modulated its expression; nonetheless, shedding
might occur. Finally, hyperthermia might alter the kinetics of
MAb-antigen interaction; however, we have demonstrated that the
binding kinetics of 81C6 to tenascin are the same over a tempera-
ture range of 37-450C (Hauck et al, 1996).
Ofparticular relevance to the current study is the potential effect
of hyperthermia on MAb diffusion through the tumour intersti-
tium. The Stokes-Einstein equation for calculating the diffusion
coefficient, D = RT/(NA6tcx), indicates that D is directly propor-
tional to the temperature (Curry, 1984). In addition, hyperthermia
could decrease the viscosity of the interstitial fluid in the tumour
(represented by in the above equation). Given the short range of
a-particles, improving the diffusion of a 211At-labelled MAb
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should increase its cytotoxicity in tumours with radii greater than
the 55-70 jim range of21'At a-particles.
With 21 At-ch8lC6, binding to the spheroid surface would be
expected to result in cell kill to a maximum depth of70gm. Given
the 100-jim initial radius of these spheroids, cell killing at the
centre ofthe spheroid would require diffusion ofthe MAb into the
spheroid, a process that we had hoped would be facilitated by
hyperthermia. Unfortunately, there was no evidence for improved
MAb distribution within the spheroids by hyperthermia, either
measured indirectly by growth delay orby direct visual inspection
ofspheroid autoradiographs.
The effect ofhyperthermia on MAb diffusion is complicated by
the 'binding site barrier' (van Osdol et al, 1991) with the conse-
quence that high affinity MAbs bind to the first antigen encoun-
tered, thereby retarding its diffusion to the deeper layers of the
tumour. This is consistent with observations ofhigher penetration
ofMAb into tumour spheroids with lower affinity MAbs or lower
antigen concentrations (McFadden and Kwok, 1988; Langmuir et
al, 1992b). Because ch8lC6 has a high affinity for tenascin (KA
approximately 1.4 x 109 M-1) (Hauck et al, 1996), the binding site
barrier may have impeded its penetration with the D-247 MG
tenascin-positive spheroids. Hyperthermia did not exacerbate this
barrier to penetration as increasing the incubation temperature
from 37°C to 42°C does nothave a significant effect on the associ-
ation or disassociation rate constants, or the equilibrium constant
for the binding ofradioiodinated 81C6 to D-247 MG glioma cells
in vitro (Hauck et al, 1996).
Autoradiographs of these glioma spheroids exhibited patterns
consistent with a binding-site barrier as binding of ch8lC6 was
largely confined to the outer layers of the spheroids (Figures 4
and 5). Although autoradiographs of spheroids might have been
used to directly measure alterations in the depth of MAb penetra-
tion from a 1-h hyperthermia treatment, measurements taken on a
spheroid section thatdid notinclude the maximumdiameter would
overestimate depth of penetration. Moreover, as enhancing cyto-
toxicity was the practical goal of this study, we chose to use
growth delay as the end point to assess the effect ofhyperthermia
on MAb distribution.
Experiments were performed using unlabelled MAb in an
attempt to saturate outerlayers ofantigen andfacilitate penetration
ofthe labelled MAb into the spheroid. Intact MAb was selected as
the blocking agent instead of monovalent Fab fragments for
several reasons. The lower molecular weight and avidity of the
Fab should facilitate its diffusion into inner spheroid regions;
however, it is the outer regions of the spheroid in which blocking
of labelled MAb binding is required. In addition, because the
affinity of 81C6 Fab is more than tenfold lower than intact MAb
(Hauck et al, 1996), Fab bound to the outer spheroid layers would
be a poor competitor for subsequently administered labelled intact
MAb. Essand and colleagues (1995a,b) have demonstrated that
increased penetration of labelled MAb into spheroids could be
accomplished by previous administration ofcold MAb. In DU 145
spheroids of about 800 jm diameter, this strategy increased
labelled MAb delivery by about a factor of six at a penetration
depth of200 jim.
In the current study, no evidence for improved penetration of
labelled MAb was seen either in the autoradiographs or in the
growth delay experiments when spheroids were preincubated with
an excess ofcold MAb. In fact, the addition ofunlabelled MAb had
a deleterious effect as this tactic decreased growth delay in the 125
and 250 kBq ml-' groups. This presumably reflects competition of
cold MAb for tenascin binding sites in outer spheroid layers. It is
not clearwhy we were not able to improve spheroid penetration by
blocking outer-layer binding with cold MAb. The amount of cold
MAb that we used was at least 40 times higher than labelled MAb;
the molar ratios of cold-labelled E4 MAb was 20:1 in one study
(Essand et al, 1995a) and not indicated in the other (Essand et al,
1995b). Differences between ourconditions andthose ofEssand et
al (1995a,b) that might be relevant include our use of smaller
spheroids (200 ,um v 800 ,um) and the fact that the 81C6 MAb
reacts with a highly expressed, extracellular matrix antigen,
whereas E4 binds to a cell surface antigen.
In summary, this study has demonstrated that a 1 h, 42°C hyper-
thermia treatment does not significantly improve cytotoxicity of
21'At-labelled ch8lC6 MAb in glioma spheroids as measured by
spheroid growth delay. Longer hyperthermia treatments that
enhance MAb uptake in vivo, such as 4 h at 41.8°C (Hauck et al,
1997), may still have a positive effect on the distribution ofMAbs
and, possibly, their cytotoxicity in vivo; however, the deleterious
effects ofprolonged hyperthermia treatment itselfforthese human
glioma spheroids prevented the testing of these conditions in this
in vitro model. Nonetheless, the significantly enhanced MAb
tumour uptake and tumour-to-normal-tissue ratios obtained with
hyperthermia in xenograft models suggests there may be a place
forhyperthermia/labelled MAb combination therapy in the clinical
armamentarium for cancer treatment. However, further studies are
needed to better define the critical mechanisms responsible for
hyperthermic enhancement of mAb uptake and cytotoxicity, as
well as the optimal radionuclide for combining hyperthermia with
radioimmunotherapy.
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